PerspectiveDuchenne Muscular Dystrophy

Toward an Oligonucleotide Therapy for Duchenne Muscular Dystrophy: A Complex Development Challenge

Science Translational Medicine  31 Mar 2010:
Vol. 2, Issue 25, pp. 25ps15
DOI: 10.1126/scitranslmed.3000512

You are currently viewing the abstract.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Abstract

Antisense oligonucleotide (AO)–mediated exon skipping is a promising new therapy for Duchenne muscular dystrophy (DMD), recently demonstrating proof of principle for restoring the absent dystrophin protein in DMD patients. However, the range of AO chemistries available for exon skipping is limited; effective systemic dystrophin protein restoration has yet to be demonstrated and will be required for disease modification in patients; and the current approach is mutation-specific, necessitating the development of multiple AO drugs to treat all DMD patients. This is therefore a highly complex drug development challenge.

Footnotes

  • Citation: M. J. A. Wood, Toward an oligonucleotide therapy for Duchenne muscular dystrophy: A complex development challenge. Sci. Transl. Med. 2, 25ps15 (2010).

View Full Text